Geographic Atrophy
FDA Approves Extended Dosing for Astellas’ Izervay, Intensifying Competition in Geographic Atrophy Treatment
Izervay, Astellas, FDA approval, extended dosing, geographic atrophy, age-related macular degeneration, Syfovre, Apellis, eye treatment
FDA Approves Extended Dosing for Astellas’ Izervay in Geographic Atrophy Treatment
Izervay, avacincaptad pegol, geographic atrophy, age-related macular degeneration, FDA approval, extended dosing, Astellas Pharma
Bausch + Lomb Collaborates with City Therapeutics on Novel RNAi-Based Treatment for Geographic Atrophy
Bausch + Lomb, City Therapeutics, RNA interference (RNAi), Geographic atrophy (GA), Age-related macular degeneration (AMD), Strategic collaboration, Ophthalmologic diseases
Bausch + Lomb Enters Strategic Collaboration with City Therapeutics for RNAi-Based Eye Disease Treatment
Bausch + Lomb, City Therapeutics, RNAi, eye disease, geographic atrophy, age-related macular degeneration, strategic collaboration
Aviceda Secures $200M Series C Funding to Advance Ocular Drug AVD-104 into Late-Stage Trials
Aviceda Therapeutics, AVD-104, Geographic Atrophy, Age-Related Macular Degeneration, Diabetic Macular Edema, Series C Funding, Late-Stage Clinical Trials
FDA Issues Complete Response Letter to Astellas for IZERVAY Supplemental New Drug Application
FDA, Astellas, IZERVAY, geographic atrophy, age-related macular degeneration, Complete Response Letter, supplemental New Drug Application
Astellas Withdraws European Application for Geographic Atrophy Treatment Izervay
Astellas, Izervay, geographic atrophy, European application withdrawal, avacincaptad pegol
Astellas Launches First Direct-to-Consumer Campaign for IZERVAY, Highlighting Its Potential to Slow Geographic Atrophy Progression
IZERVAY, geographic atrophy, age-related macular degeneration, direct-to-consumer campaign, Astellas Pharma